Sánchez, Antonio JPuerta, CarmenBallester, SaraGonzález, PazArriaga, AngelGarcía-Merino, Antonio2023-02-142023-02-142005-11J Neuroimmunol. 2005 Nov;168(1-2):13-20.0165-5728http://hdl.handle.net/20.500.12105/15503Rolipram suppresses experimental autoimmune encephalomyelitis (EAE) and diminishes cell infiltration of the central nervous system (CNS). In Lewis rats with EAE, rolipram reduced matrix metalloproteinase-9 (MMP-9) gene expression in lymph node cells (LNCs) and spinal cord, decreased basal levels of nuclear (p50/p65) NF-kappaB in LNCs from treated rats, and impaired CD3 mediated NF-kappaB translocation. Rolipram reduced the luciferase activity directed by the NF-kappaB binding site of the MMP-9 gene in lymphocytes. It also diminished NF-kappaB activity and the ability of a myelin basic protein (MBP) specific cell line to migrate across artificial basement membranes. IL-2 induced MMP-9 proteolytic activity was only slightly reduced indicating that additional factors contribute to inhibit cell migration mediated by rolipram.engAMhttp://creativecommons.org/licenses/by-nc-nd/4.0/Experimental autoimmune encephalomyelitisRolipramNuclear factor kappa BMatrix metalloproteinase-9AnimalsCell MovementCells, CulturedDisease Models, AnimalDose-Response Relationship, DrugDrug InteractionsElectrophoretic Mobility Shift AssayEncephalomyelitis, Autoimmune, ExperimentalGene ExpressionLuciferasesLymph NodesLymphocytesMatrix Metalloproteinase 9Myelin Basic ProteinNF-kappa BPhosphodiesterase InhibitorsRNA, MessengerRatsRats, Inbred LewReverse Transcriptase Polymerase Chain ReactionRolipramSpinal CordTransfectionAttribution-NonCommercial-NoDerivatives 4.0 Internacional161823791681-213-2010.1016/j.jneuroim.2005.03.024Journal of neuroimmunologyopen access